Investment Rating - The report maintains a "Buy" rating for the company [6][3]. Core Insights - The company's annual performance met expectations, with commercial product sales slightly affected by price adjustments after inclusion in the medical insurance system. However, a strong recovery in growth is anticipated in 2026 [3][9]. - The company is confident that sales of its core product, Lukanosatuzumab, will double after its inclusion in the medical insurance system, with expected revenue from this product reaching 80% of its total income [9][3]. - The report highlights that several clinical and commercialization catalysts are expected in the short term, including the upcoming release of significant data for Lukanosatuzumab [9][3]. Financial Forecast Changes - Revenue projections for 2026 have been adjusted to USD 2.608 billion, a decrease of 14.1% from previous estimates. For 2027, revenue is projected at USD 4.193 billion, down 9.8% [4]. - Gross profit for 2026 is forecasted at USD 1.870 billion, reflecting a 16.4% reduction from prior estimates, with a gross margin of 71.7% [4]. - The net profit attributable to shareholders is expected to be a loss of USD 250 million in 2026, compared to a profit of USD 50 million previously forecasted [4]. Financial Data Summary - The company achieved a total revenue of RMB 2.058 billion in 2025, with a projected increase to RMB 2.608 billion in 2026 and RMB 4.193 billion in 2027 [15]. - The net loss for 2025 is projected to be RMB 527 million, with expectations of a return to profitability in 2027 with a net profit of RMB 485 million [15]. - The company’s cash and cash equivalents are expected to be RMB 3.060 billion by the end of 2026, increasing to RMB 5.202 billion by 2028 [15].

Investment Rating - The report maintains a "Buy" rating for the company [6][3]. Core Insights - The company's annual performance met expectations, with commercial product sales slightly affected by price adjustments after inclusion in medical insurance. However, a strong recovery in growth is anticipated in 2026 [3][9]. - The company is confident that sales of its core product, Lukanosatuzumab, will double after its inclusion in medical insurance, with expected revenue from this product accounting for over 80% of its total income [9][3]. - The report highlights upcoming key data releases for Lukanosatuzumab, with significant clinical and commercial catalysts expected in the short term [9][3]. Financial Forecast Changes - Revenue projections for 2026 have been adjusted to USD 2.608 billion, a decrease of 14.1% from previous estimates. For 2027, revenue is projected at USD 4.193 billion, down 9.8% [4]. - Gross profit for 2026 is forecasted at USD 1.870 billion, reflecting a 16.4% reduction from prior estimates, with a gross margin of 71.7% [4]. - The net profit attributable to shareholders is expected to be a loss of USD 250 million in 2026, compared to a profit of USD 50 million previously forecasted [4]. Financial Data Overview - The company achieved a total revenue of RMB 2.058 billion in 2025, with a projected increase to RMB 2.608 billion in 2026 and RMB 4.193 billion in 2027 [15]. - The net loss for 2025 is projected to be RMB 527 million, with expectations of a return to profitability in 2027 with a net profit of RMB 485 million [15]. - The company’s cash and cash equivalents are expected to be RMB 3.060 billion by the end of 2026, increasing to RMB 5.202 billion by 2028 [15].

Group 1: 德琪医药 (6996 HK) - The company is expected to achieve breakeven in 2026, with a projected revenue increase of 15% to 105 million RMB in 2025 and a reduced loss of 239 million RMB [1] - The collaboration with UCB on ATG-201 is anticipated to contribute 80 million USD in recent payments, significantly enhancing performance and achieving breakeven [1][2] - The development of ATG-022 is set to provide multiple catalysts in the next 12 months, with peak sales in the gastric cancer field projected to exceed 5 billion USD [2] Group 2: 药明合联 (2268 HK) - The company recorded strong financial performance in 2025, with revenue and adjusted net profit increasing by 46.7% and 69.9% year-on-year, respectively [4] - The gross margin improved significantly by 5.4 percentage points to 36.0%, with stable operating expense ratios [4] - The company expects revenue growth to exceed 40% in 2026, driven by technical upgrades, capacity expansion, and M-end projects [4][7] Group 3: 科伦博泰生物 (6990 HK) - The company’s revenue for 2025 was 2.06 billion RMB, a 6% year-on-year increase, with confidence in doubling sales of its core product, Lukanosumab, in 2026 [8][9] - Key data releases for Lukanosumab are expected in 2026, with multiple early-stage pipelines progressing steadily [9] - The target price for the company has been adjusted down to 530 HKD, reflecting a potential upside of 25.9% [9] Group 4: 华润啤酒 (291 HK) - The company’s revenue for 2025 is projected to decline by 1.7% to 37.99 billion RMB, with beer business remaining stable while the liquor segment faces a 30.4% drop [10][11] - Beer sales volume and average price are expected to grow by 1.4% and decline by 1.4%, respectively, with a continued trend towards premiumization [10] - The target price remains at 35.90 HKD, corresponding to an 18 times forecasted P/E ratio for 2026 [11] Group 5: 中国电力 (2380 HK) - The company’s profit for 2025 is expected to decline by 13.5% to 2.91 billion RMB, primarily due to lower-than-expected operating profits from wind and solar segments [12] - The company plans to add 6.2 GW of wind/solar capacity in 2025, with conservative installation targets for 2026 [12][13] - A dividend policy is being considered to shift from a fixed ratio to a fixed amount over the next 3-5 years [13]

Core Insights - The latest version of the medical insurance drug list will be implemented on January 1, 2026, with significant updates aimed at improving access to essential medications for insured individuals [1]. Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [2]. - New drugs include treatments for critical conditions such as triple-negative breast cancer and pancreatic cancer, as well as medications for chronic diseases and rare diseases [2]. Group 2: Expanded Payment Coverage - The payment scope has been broadened for 65 drugs, with new indications included for reimbursement, such as additional targets for non-small cell lung cancer treatments and expanded age eligibility for certain rare disease medications [3]. - Adjustments have been made to align payment criteria more closely with clinical practices, such as changing the payment range for certain drugs from "previous chemotherapy" to "past chemotherapy" [3]. - Some drugs have had restrictions removed or modified, while ensuring that reimbursement is still aligned with clinical guidelines [3]. Group 3: Drug Removal and Transition Policies - A total of 29 drugs have been removed from the list, primarily those that have been clinically obsolete or not produced for an extended period [4]. - A transition policy has been established for drugs that were removed but had not successfully renewed their contracts, allowing a 6-month period for insured individuals to purchase these drugs at the original reimbursement standards [4].

Core Viewpoint - The implementation of the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)" aims to optimize the drug reimbursement system, enhancing both the efficiency of medical insurance funds and the accessibility of essential medications for the public [1] Group 1: Drug List Changes - The new drug list includes 114 new drugs, with 50 being innovative first-class drugs, while 29 drugs with lower clinical value have been removed, bringing the total to 3,253 drugs [1] - The updated list covers key areas such as oncology, rare diseases, chronic diseases, and pediatric medications [1] Group 2: New Drug Characteristics - Newly included drugs exhibit three significant characteristics: they either fill clinical treatment gaps, are superior alternatives, or offer better cost-effectiveness [1] - Specific examples include new drugs for treating triple-negative breast cancer and pancreatic cancer, which improve affordability and accessibility for patients [2] Group 3: Payment Scope Adjustments - The payment scope for 65 drugs has been revised to better align with clinical realities, such as expanding the use of certain drugs to a broader patient age range [3] - New conditions have been added for some drugs to prevent misuse while ensuring that medical insurance funds are utilized effectively [3] Group 4: Cost Reduction Initiatives - The combination of price negotiations and medical insurance reimbursements is expected to lower the cost of medications for the public [3] - A new "Commercial Health Insurance Innovative Drug List (2025)" has been introduced, including 19 high-value innovative drugs, which complements basic medical insurance and addresses diverse health needs [3] Group 5: Implementation and Accessibility - The medical insurance department has mandated that medical institutions incorporate newly added drugs into their procurement lists by the end of February [4] - A transition policy allows for a 6-month period during which patients can still purchase removed drugs at previous reimbursement rates [4] - A new feature for querying the updated basic medical insurance drug list has been launched on the National Medical Insurance Bureau's WeChat public account [4]

Core Insights - The recent adjustment to the National Medical Insurance Drug List has significantly reduced the costs of long-acting growth hormone treatments, benefiting many families [1] - The new drug list includes a high proportion of innovative drugs and aims to enhance drug accessibility for patients in urgent clinical need [2] Group 1: New Drug Additions - A total of 114 new drugs have been added to the insurance list, covering critical areas such as oncology, chronic diseases, and rare diseases [2] - The average price reduction for newly added drugs exceeds 60%, significantly alleviating the financial burden on patients [2] - Notable new drugs include innovative treatments for triple-negative breast cancer and pancreatic cancer, as well as long-acting growth hormone for children [2] Group 2: Optimization of Existing Drugs - The payment scope for 65 existing drugs has been optimized, including expanded indications for certain medications [3] - Adjustments have been made to ensure that the descriptions of drug payment scopes align more closely with clinical realities [3] Group 3: Policy Measures - The government has implemented a series of policies to ensure that negotiated drugs are effectively integrated into hospitals and accessible to patients [3] - Medical institutions are required to hold pharmacy meetings to incorporate new drugs into their procurement lists by February 2026 [3] Group 4: Industry Impact - The adjustment has led to the removal of 29 drugs that have lower efficacy or better alternatives available, thereby optimizing the use of medical insurance funds [4] - The inclusion of numerous innovative drugs indicates a strengthening of domestic pharmaceutical companies' research and development capabilities [4][5] - Major companies like Heng Rui Medicine and Innovent Biologics have successfully introduced multiple innovative drugs into the new insurance list [5]

Core Insights - The recent adjustment to the National Medical Insurance Drug List has significantly reduced the costs of long-acting growth hormone treatments, benefiting many families [1] - The new drug list includes a substantial number of innovative drugs, with an average price reduction of over 60%, aimed at improving patient access to essential medications [2] Group 1: New Drug Additions - A total of 114 new drugs have been added to the insurance list, covering critical areas such as oncology, chronic diseases, and rare diseases [2] - Notable new drugs include innovative treatments for triple-negative breast cancer and pancreatic cancer, as well as long-acting growth hormone for children [2][4] - The new drugs are characterized by either filling clinical treatment gaps, being superior to existing options, or offering better cost-effectiveness [2] Group 2: Existing Drug Adjustments - The payment scope for 65 existing drugs has been optimized, including expanding the target population for certain medications [3] - Adjustments have been made to align drug descriptions more closely with clinical realities, facilitating easier prescription by healthcare providers [3] Group 3: Policy and Industry Impact - The adjustment aims to optimize the use of medical insurance funds, allowing for the introduction of innovative drugs while removing less effective ones [4] - The removal of 29 drugs primarily targets those with lower cost-effectiveness or available alternatives, with minimal impact on most patients [4] - The inclusion of numerous innovative drugs reflects the strengthening of domestic pharmaceutical companies' R&D capabilities [5] Group 4: Financial Implications - The National Medical Insurance Bureau has adjusted the drug list for eight consecutive years, adding a total of 949 new drugs, with significant financial implications for the pharmaceutical market [5] - The insurance fund has spent over 460 billion yuan on negotiated drug expenditures, driving sales growth exceeding 600 billion yuan [5]

Core Insights - The latest medical insurance drug list has been officially implemented as of January 1, 2026, featuring significant updates that enhance accessibility and affordability for insured individuals [1]. Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as new category 1 drugs, marking a record high in both quantity and proportion [2][3]. - Notable new drugs include treatments for triple-negative breast cancer, pancreatic cancer, and various chronic conditions, such as long-acting growth hormone injections and diabetes medications [3]. Group 2: Expanded Payment Scope - The payment scope has been broadened to include 65 drugs with new indications, allowing for better access to treatments for conditions like non-small cell lung cancer and rare diseases [4]. - Adjustments have been made to align payment criteria more closely with clinical practices, such as changing the payment criteria for certain drugs to reflect actual treatment scenarios [4]. Group 3: Restrictions and Conditions - New restrictions have been introduced for certain drugs to prevent misuse, ensuring that insurance funds are utilized effectively [5]. - Some drugs have had non-core restrictions removed, but the fundamental usage requirements remain unchanged, emphasizing the need for clinical discretion [5]. Group 4: Structural Adjustments - A total of 29 drugs have been removed from the list, primarily those that have been clinically obsolete or are no longer in production [6]. - A transition period of six months has been established for drugs that were removed but were under negotiation, allowing insured individuals to continue purchasing them at previous reimbursement rates until June 2026 [6]. Group 5: User Accessibility - The National Medical Insurance Bureau has launched a new feature on its WeChat account for users to query the updated basic medical insurance drug list easily [6].

Core Insights - The latest medical insurance drug list will be implemented on January 1, 2026, featuring significant updates that focus on clinical needs and expand access to essential medications [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [1] - Notable new drugs include treatments for triple-negative breast cancer, pancreatic cancer, and long-acting growth hormone injections for children with growth deficiencies [3] Group 2: Expanded Payment Coverage - The payment coverage has been expanded for 65 drugs, with new indications included for existing medications, such as additional targets for non-small cell lung cancer treatments and broader age eligibility for rare disease treatments [4] - Adjustments have been made to payment criteria to better align with clinical practices, such as changing the payment range for certain drugs from "previous chemotherapy" to "past chemotherapy" [4] Group 3: Restrictions and Adjustments - New limitations have been introduced for certain drugs to prevent misuse, ensuring that insurance funds are utilized effectively [5] - Some drugs have had non-core restrictions removed, but the fundamental usage requirements remain unchanged, such as the diabetes medication semaglutide [5] Group 4: Drug List Structure and Transition Policies - The updated list has removed 29 drugs that are either clinically obsolete or have not been produced for an extended period, including several that did not successfully renew their negotiation agreements [6] - A transition policy has been established, allowing a 6-month period for patients to purchase removed drugs at previous reimbursement standards [6] - A new query function for the basic medical insurance directory has been launched on the National Medical Insurance Bureau's WeChat account for easier access to the updated list [6]

Core Insights - The latest medical insurance drug list will be implemented on January 1, 2026, featuring significant updates that benefit insured individuals [1][9]. Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [10]. - New drugs include treatments for critical conditions such as triple-negative breast cancer and pancreatic cancer, as well as medications for growth hormone deficiency in children and diabetes [12]. Group 2: Expanded Payment Coverage - The payment scope has been expanded for 65 drugs, with new indications included for several medications, such as additional targets for non-small cell lung cancer treatment and expanded age eligibility for narcolepsy treatment [4][12]. - Adjustments have been made to payment criteria to better align with clinical practices, such as changing the payment scope for certain drugs from "previous chemotherapy" to "past chemotherapy" [4][12]. Group 3: Drug Removals - A total of 29 drugs have been removed from the list, primarily those that have been clinically obsolete or not produced for an extended period [5][14]. - A transition policy has been established, allowing a 6-month period for insured individuals to purchase removed drugs at the original reimbursement standards [14]. Group 4: Accessibility and User Support - The National Medical Insurance Bureau has launched a new function on its WeChat public account for users to query the updated basic medical insurance directory [8][16].